China Antibody-B (03681) issued an announcement. Since the prerequisites contained in the 13 subscription agreements have been met, according to...
According to Zhitong Finance App News, China Antibody-B (03681) issued an announcement. Since the prerequisites contained in the 13 subscription agreements have been met, the 13 subscription agreements were completed on January 12, 2024 in accordance with the terms and conditions of the relevant subscription agreements. A total of 48.32,100 shares, equivalent to approximately 4.67% of the company's issued share capital immediately before the completion of individual subscription agreements; and approximately 4.46% of the company's issued share capital expanded by issuing subscription shares, which have been issued to subscribers at a subscription price of HK$1.29 per subscription share. The net proceeds from the subscription process of approximately HK$62.05 million will be applied as disclosed in the announcement. As agreed by the contracting parties, the remaining two subscription agreements are expected to be completed on or before January 31, 2024 for a total of 8.526 million subscription shares at a subscription price of HK$1.29 per share.